
Profitability, historical returns, and peer comparisons.
According to Immunovant, Inc.’s latest financial reports and current stock price. The company's current ROE is -69.59%. This represents a change of 277.48% compared to the average of -18.43% of the last 4 quarters.
The mean historical ROE of Immunovant, Inc. over the last ten years is 976.09%. The current -69.59% ROE has changed -107.13% with respect to the historical average. Over the past ten years (40 quarters), IMVT's ROE was at its highest in in the June 2018 quarter at 291.86%. The ROE was at its lowest in in the December 2024 quarter at -31.51%.
Average
976.09%
Median
-41.98%
Minimum
-70.57%
Maximum
9.14%
Discovering the peaks and valleys of Immunovant, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.77%
Maximum Annual ROE = 9.14%
Minimum Annual Increase = -100.02%
Minimum Annual ROE = -70.57%
| Year | ROE | Change |
|---|---|---|
| 2026 | -59.30% | 1.38% |
| 2025 | -58.50% | 39.35% |
| 2024 | -41.98% | -27.87% |
| 2023 | -58.20% | 74.45% |
| 2022 | -33.36% | 21.56% |
| 2021 | -27.44% | -61.12% |
| 2020 | -70.57% | 3.77% |
| 2019 | -1.82% | -100.02% |
The current ROE of Immunovant, Inc. (IMVT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-53.26%
5-year avg
-50.27%
10-year avg
976.09%
Immunovant, Inc.’s ROE is greater than Zenas BioPharma, Inc. (-189.68%), less than Q32 Bio Inc. (47.92%), greater than Annexon, Inc. (-106.15%), less than TG Therapeutics, Inc. (72.30%), less than AnaptysBio, Inc. (2.52%), greater than Immunic, Inc. (-157.89%), greater than Aclaris Therapeutics, Inc. (-61.65%), greater than Cabaletta Bio, Inc. (-128.27%), greater than First Tracks Biotherapeutics Inc (-72.93%), greater than Cullinan Therapeutics, Inc. (-52.89%),
| Company | ROE | Market cap |
|---|---|---|
| -189.68% | $1.85B | |
| 47.92% | $267.03M | |
| -106.15% | $709.44M | |
| 72.30% | $9.43B | |
| 2.52% | $1.42B | |
| -157.89% | $108.34M | |
| -61.65% | $541.69M | |
| -128.27% | $240.75M | |
| -72.93% | $2.06B | |
| -52.89% | $767.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunovant, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immunovant, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Immunovant, Inc.'s ROE?
How is the ROE calculated for Immunovant, Inc. (IMVT)?
What is the highest ROE for Immunovant, Inc. (IMVT)?
What is the 3-year average ROE for Immunovant, Inc. (IMVT)?
What is the 5-year average ROE for Immunovant, Inc. (IMVT)?
How does the current ROE for Immunovant, Inc. (IMVT) compare to its historical average?